<h1>ASH Announces Editors-in-Chief of Two New <em>Blood</em> Journals</h1>
Drs. Willem Fibbe and Patrick Gallagher selected to head new specialty hematology publications
(WASHINGTON, Oct. 9, 2024) — The American Society of Hematology (ASH) has selected Willem Fibbe, MD, and Patrick Gallagher, MD, to serve as the inaugural editors-in-chief of the latest additions to the Blood journals portfolio: Blood Immunology and Cellular Therapy (Blood ICT) and Blood Red Cells and Iron (Blood RCI). The ASH Executive Committee selected them following an extensive international search.
Blood ICT and Blood RCI, both set to launch in early 2025, will be peer-reviewed, open access journals publishing high-quality original research in specialized blood disease areas. Blood ICT will cover cellular and non-cellular immunotherapies for hematologic conditions as well as the underlying immunology, including research on monoclonal antibodies, CAR-T cells, gene therapies, and more. Blood RCI will focus on red blood cells and feature research in areas such as inherited and acquired anemias, sickle cell disease, and cell production.
Blood ICT and Blood RCI will join ASH’s extensive Blood journals portfolio — Blood, Blood Advances, Blood Neoplasia, Blood Global Hematology, and Blood Vessels, Thrombosis & Hemostasis, to meet the demands of the growing field of hematology and foster community in these areas of research.
“We are proud of the strides we've made in growing the Blood journals portfolio to address the diverse needs of hematology and excited to welcome two new journals led by Drs. Fibbe and Gallagher who will bring their unique expertise and vision to the Blood journals,” said Mohandas Narla, DSc, ASH president and distinguished scientist at New York Blood Center Enterprises. “Blood ICT and Blood RCI will continue upholding ASH’s long-standing commitment to publishing world-class, cutting-edge research and will provide unique forums for these more focused areas of hematology.”
Dr. Fibbe, the inaugural editor-in-chief of Blood ICT, is the emeritus professor of hematology and stem cell biology at Leiden University Medical Centre in the Netherlands, and a member of the Netherlands Clinical Trial Competent Authority. Dr. Fibbe brings extensive international leadership experience to his role as a former president of the European Hematology Association and a committee member for organizations including the World Health Organization, the International Society for Experimental Hematology, and NetCord. His research focuses on hematopoietic stem cell biology, regenerative medicine, and cellular therapies.
“The therapies we will cover in Blood ICT apply broadly to both hematologic malignancies and classical (non-malignant) blood disorders. There is hardly any area of hematology that hasn’t benefited from these innovations,” said Dr. Fibbe. “I am excited about the opportunity to contribute to the growth and success of this new journal.”
Dr. Gallagher, the incoming editor-in-chief of Blood RCI, is the director of the Center for Perinatal Research at Nationwide Children’s Hospital and professor of pediatrics at The Ohio State University. Dr. Gallagher is a longstanding ASH member and currently serves on ASH’s Ernest Beutler Award Study Section, Working Group on Maternal Health in Hematology, and Subcommittee on Red Cell Biology. His research focuses on blood cell production, particularly in conditions that affect the production of red blood cells.
“Over the past several years, a lot of technical advances in red cell and iron biology topics have led to improvements in everything from laboratory diagnosis to consideration for treatment strategies,” said Dr. Gallagher. “In addition to covering these topics in Blood RCI, I hope to provide a home for other focused research that has been the focal point of my career.”
Both Blood ICT and Blood RCI will launch in early 2025. For more information about the journals, please visit the Blood journals website.
The American Society of Hematology (ASH) (hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. Since 1958, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology.
The Blood journals (https://ashpublications.org/journals) are the premier source for basic, translational, and clinical hematological research. The Blood journals publish more peer-reviewed hematology research than any other academic journals worldwide.
Claire Whetzel, 202-629-5085
Drs. Willem Fibbe and Patrick Gallagher selected to head new specialty hematology publications
(WASHINGTON, Oct. 9, 2024) — The American Society of Hematology (ASH) has selected Willem Fibbe, MD, and Patrick Gallagher, MD, to serve as the inaugural editors-in-chief of the latest additions to the Blood journals portfolio: Blood Immunology and Cellular Therapy (Blood ICT) and Blood Red Cells and Iron (Blood RCI). The ASH Executive Committee selected them following an extensive international search.
Blood ICT and Blood RCI, both set to launch in early 2025, will be peer-reviewed, open access journals publishing high-quality original research in specialized blood disease areas. Blood ICT will cover cellular and non-cellular immunotherapies for hematologic conditions as well as the underlying immunology, including research on monoclonal antibodies, CAR-T cells, gene therapies, and more. Blood RCI will focus on red blood cells and feature research in areas such as inherited and acquired anemias, sickle cell disease, and cell production.
Blood ICT and Blood RCI will join ASH’s extensive Blood journals portfolio — Blood, Blood Advances, Blood Neoplasia, Blood Global Hematology, and Blood Vessels, Thrombosis & Hemostasis, to meet the demands of the growing field of hematology and foster community in these areas of research.
“We are proud of the strides we've made in growing the Blood journals portfolio to address the diverse needs of hematology and excited to welcome two new journals led by Drs. Fibbe and Gallagher who will bring their unique expertise and vision to the Blood journals,” said Mohandas Narla, DSc, ASH president and distinguished scientist at New York Blood Center Enterprises. “Blood ICT and Blood RCI will continue upholding ASH’s long-standing commitment to publishing world-class, cutting-edge research and will provide unique forums for these more focused areas of hematology.”
Dr. Fibbe, the inaugural editor-in-chief of Blood ICT, is the emeritus professor of hematology and stem cell biology at Leiden University Medical Centre in the Netherlands, and a member of the Netherlands Clinical Trial Competent Authority. Dr. Fibbe brings extensive international leadership experience to his role as a former president of the European Hematology Association and a committee member for organizations including the World Health Organization, the International Society for Experimental Hematology, and NetCord. His research focuses on hematopoietic stem cell biology, regenerative medicine, and cellular therapies.
“The therapies we will cover in Blood ICT apply broadly to both hematologic malignancies and classical (non-malignant) blood disorders. There is hardly any area of hematology that hasn’t benefited from these innovations,” said Dr. Fibbe. “I am excited about the opportunity to contribute to the growth and success of this new journal.”
Dr. Gallagher, the incoming editor-in-chief of Blood RCI, is the director of the Center for Perinatal Research at Nationwide Children’s Hospital and professor of pediatrics at The Ohio State University. Dr. Gallagher is a longstanding ASH member and currently serves on ASH’s Ernest Beutler Award Study Section, Working Group on Maternal Health in Hematology, and Subcommittee on Red Cell Biology. His research focuses on blood cell production, particularly in conditions that affect the production of red blood cells.
“Over the past several years, a lot of technical advances in red cell and iron biology topics have led to improvements in everything from laboratory diagnosis to consideration for treatment strategies,” said Dr. Gallagher. “In addition to covering these topics in Blood RCI, I hope to provide a home for other focused research that has been the focal point of my career.”
Both Blood ICT and Blood RCI will launch in early 2025. For more information about the journals, please visit the Blood journals website.
The American Society of Hematology (ASH) (hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. Since 1958, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology.
The Blood journals (https://ashpublications.org/journals) are the premier source for basic, translational, and clinical hematological research. The Blood journals publish more peer-reviewed hematology research than any other academic journals worldwide.
Claire Whetzel, 202-629-5085